426 related articles for article (PubMed ID: 32799335)
21. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
22. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
23. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Poratti M; Marzaro G
Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
[TBL] [Abstract][Full Text] [Related]
24. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
25. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
26. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D; Bardia A; Sellers WR
Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
[TBL] [Abstract][Full Text] [Related]
27. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.
Asghar US; Kanani R; Roylance R; Mittnacht S
JCO Precis Oncol; 2022 Jan; 6():e2100002. PubMed ID: 35005994
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
30. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA; Selby C
Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
[TBL] [Abstract][Full Text] [Related]
31. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
32. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Coussy F; Deluche E; Pistilli B; Ladoire S; Ferrero JM; Cottu P
Bull Cancer; 2021 Sep; 108(9):843-854. PubMed ID: 34154797
[TBL] [Abstract][Full Text] [Related]
33. Lysosomal trapping of palbociclib and its functional implications.
Llanos S; Megias D; Blanco-Aparicio C; Hernández-Encinas E; Rovira M; Pietrocola F; Serrano M
Oncogene; 2019 May; 38(20):3886-3902. PubMed ID: 30692638
[TBL] [Abstract][Full Text] [Related]
34. Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
Iuliani M; Simonetti S; Ribelli G; Napolitano A; Longo UG; Vincenzi B; Orsaria P; Denaro V; Tonini G; Santini D; Francesco P
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269621
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
36. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
Thibault S; Hu W; Hirakawa B; Kalabat D; Franks T; Sung T; Khoh-Reiter S; Lu S; Finkelstein M; Jessen B; Sacaan A
Mol Cancer Ther; 2019 Feb; 18(2):257-266. PubMed ID: 30401694
[TBL] [Abstract][Full Text] [Related]
37. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
39. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
40. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
